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Sex	in	mammals	is	genetically	determined	and	is	defined	at	the	cellular	level	by	sex	chromosome	complement	
(XY	males	and	XX	females).	The	Y	chromosome–linked	gene	sex-determining	region	Y	(SRY)	is	believed	to	be	
the	master	initiator	of	male	sex	determination	in	almost	all	eutherian	and	metatherian	mammals,	functioning	
to	upregulate	expression	of	its	direct	target	gene	Sry-related	HMG	box–containing	gene	9	(SOX9).	Data	suggest	
that	SRY	evolved	from	SOX3,	although	there	is	no	direct	functional	evidence	to	support	this	hypothesis.	Indeed,	
loss-of-function	mutations	in	SOX3	do	not	affect	sex	determination	in	mice	or	humans.	To	further	investigate	
Sox3	function	in	vivo,	we	generated	transgenic	mice	overexpressing	Sox3.	Here,	we	report	that	in	one	of	these	
transgenic	lines,	Sox3	was	ectopically	expressed	in	the	bipotential	gonad	and	that	this	led	to	frequent	complete	
XX	male	sex	reversal.	Further	analysis	indicated	that	Sox3	induced	testis	differentiation	in	this	particular	line	of	
mice	by	upregulating	expression	of	Sox9	via	a	similar	mechanism	to	Sry.	Importantly,	we	also	identified	genomic	
rearrangements	within	the	SOX3	regulatory	region	in	three	patients	with	XX	male	sex	reversal.	Together,	these	
data	suggest	that	SOX3	and	SRY	are	functionally	interchangeable	in	sex	determination	and	support	the	notion	
that	SRY	evolved	from	SOX3	via	a	regulatory	mutation	that	led	to	its	de	novo	expression	in	the	early	gonad.
Introduction
Sex in mammals is genetically determined and is defined at the 
cellular level by sex chromosome complement (XY males and XX 
females) and at the phenotypic level by the development of gen-
der-specific anatomy, physiology, and behavior. Disorders of sexual 
development (DSDs) in humans are characterized by a complete 
or partial mismatch between genetic sex and phenotypic sex. Col-
lectively, DSDs occur in at least 1 in 100 live births (1) and include 
relatively mild forms such as hypospadias (1 in 500 births) as well 
as more severe conditions such as ambiguous genitalia (1 in 4,500 
births) and complete sex reversal (46, XY females and 46, XX males; 
1 in 20,000 births). Although the etiology of many DSDs is not 
known, some cases of complete XX male and XY female sex rever-
sal are associated with translocations or mutations of the Y-linked 
testis-determining gene SRY (sex-determining region Y) (2–8). SRY 
encodes a transcription factor that contains a highly conserved 
high-mobility group (HMG) DNA-binding domain and poorly 
conserved N- and C-terminal domains. Gain-of-function and loss-
of-function studies in mice have demonstrated that Sry is necessary 
and sufficient for testis development (4, 7). Indeed, except in two 
species of the vole Ellobius (9) and the spiny rat (10), which lack the 
gene, SRY is believed to function as the master regulator of male sex 
determination in all therian (non-egg-laying) mammals (11).
The gonads develop from a band of mesoderm, the genital ridge 
(GR), that lies ventrally subjacent to the mesonephros, and together 
these constitute the urogenital ridge. The GR is considered to be 
bipotential, as it contains precursors that can differentiate into tes-
tis- or ovary-specific cell lineages (12). In mice, Sry is expressed in 
a transient center-to-pole wave in the XY GR from approximately 
10.5 to 12.5 dpc (13, 14). Analysis of hypomorphic Sry alleles and 
inducible Sry transgenic mice indicate that the level of Sry activity 
must exceed a critical threshold within a developmental window of 
approximately 6 hours (12–15 tail somite [ts] stage) for irreversible 
commitment to a male fate (15–17). Despite its pivotal role in direct-
ing male differentiation, it appears that the sole critical function of 
Sry in sex determination is to upregulate its direct target gene Sox9 
(Sry-related HMG box–containing gene 9), thereby initiating Ser-
toli cell differentiation (18–20). Sertoli cells subsequently undergo 
a period of rapid proliferation, aided by Sox9/Fgf9 and Sox9/Pgd2 
positive feedback loops (21, 22), and migrate and surround germ 
cells within the gonad to form testis cords. Sertoli cells also drive the 
male-specific migration of cells from the underlying mesonephros 
into the gonad. These are mostly endothelial cells that give rise to 
the coelomic vessel and other testis-specific vasculature (23). By 12.5 
dpc, steroidogenic Leydig cells have differentiated and, just 48 hours 
after Sry begins to initiate the male pathway, the early testis already 
has a highly organized stereotypical structure and is morphologi-
cally distinct from the ovary, which remains a mass of germ cells 
scattered within the gonadal mesenchyme.
Although female development has traditionally been considered 
by some to be a “default” pathway, it is now clear that sexual fate is 
determined by a balance of opposing signals within the gonad, in 
which Sry exerts a dominant masculinizing influence (22, 24). For 
example, loss-of-function mutations in Wnt4 and Rspo1 cause par-
tial XX male sex reversal, indicating that canonical Wnt signaling 
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predisposes the gonad to an ovarian fate (22, 25–29). Furthermore, 
gain-of-function mutations in Wnt4 and Ctnnb1 induce XY female 
sex reversal. While it is possible that high levels of pro-ovarian sig-
nals could block Sry activity, the evidence so far suggests that the 
effect of high levels of β-catenin is to prevent the maintenance of 
Sox9 expression (27, 29, 30). Unexplained cases of SRY-negative XX 
male sex reversal in humans may therefore arise from loss-of-func-
tion mutations in members of the pro-ovarian pathway (such as 
canonical Wnt signaling components) or gain-of-function muta-
tions in genes that mimic SRY activity, of which members of the 
SOX gene family are good candidates.
SRY-related HMG box–containing gene 3 (SOX3) is a single-
exon gene located in a highly conserved region of the X chromo-
some in therian mammals (31–33). Other vertebrate species also 
possess homologs of SOX3, but none of these have been found to 
be sex-linked, even in prototherian mammals, such as the echid-
na (34). Of the 20 SOX genes in the mammalian genome, SOX3 
encodes a protein that is most similar to SRY, sharing 67% amino 
acid identity (and 90% similarity) across the DNA-binding HMG 
domain (31, 35). Comparative sequence data, coupled with molec-
ular and cytogenetic studies of sex chromosomes, have led to the 
hypothesis that SRY arose during early mammalian evolution 
from a gain-of-function mutation in the proto-Y allele of SOX3. 
This mutation is thought to have activated gonadal expression of 
the proto-Y SOX3 allele, resulting in the emergence of a novel sex 
determination switch that is specific to therian mammals (32, 36). 
Consistent with this hypothesis, Sox3 expression is exceedingly 
low or absent in the developing gonads of mice and marsupials 
(33, 37). Sox3 is, however, widely expressed in the central nervous 
system of vertebrate embryos and is required for normal brain 
development and function in mice and humans, as well as in pitu-
itary and craniofacial development (31, 38–44). Importantly, mice 
and humans with mutations in SOX3 do not show any defects 
in sex determination, although postnatal differentiation of some 
spermatogonia and the survival of some follicles are affected in 
Sox3-null mice (40, 45, 46). Thus, although SOX3 does not nor-
mally function in sex determination, the proposed evolutionary 
link between SOX3 and SRY raises the intriguing possibility that 
certain gain-of-function mutations in SOX3 may cause XX male 
sex reversal in mice and humans.
In addition to loss-of-function mutations of SOX3, duplications 
of the locus can also lead to pituitary hormone deficiencies in 
humans (38, 41, 47). This was assumed to be due to overexpres-
sion, and therefore, to investigate this further, transgenic mice 
were derived using a large mouse Sox3 genomic fragment. Some 
of these mice developed CNS abnormalities (P. Thomas, unpub-
lished observations). However, here we describe a transgenic model 
of complete XX male sex reversal in which Sox3 is ectopically 
expressed in the developing XX gonads due to a position effect. 
Initiation of the testis pathway in XX hemizygous transgenic 
(Tg/+) gonads induced Sox9 upregulation, Sertoli cell differentia-
tion, testis cord formation, and generation of a male-specific vas-
culature. Cotransfection assays using the recently identified Sox9 
testis-specific enhancer element (TESCO; ref. 18) showed that 
SOX3, like SRY, had modest transactivation activity and func-
tioned synergistically with steroidogenic factor–1 (SF1) in this 
context. Importantly, Sox3 failed to induce XX testis development 
in gonads that lacked Sox9. We also present 3 patients with XX 
male sex reversal, each of which has a unique genomic rearrange-
ment of the SOX3 regulatory region. Together, these data suggest 
that Sox3 gain-of-function in the developing gonad induces testis 
development by functioning as a surrogate for Sry. Our findings 
also provide important functional evidence to support the long-
standing hypothesis that Sox3 is the evolutionary precursor of Sry 
and suggest that rearrangements of SOX3 are a relatively frequent 
cause of XX male sex reversal in humans.
Results
Complete XX male sex reversal exhibited in a line of Sox3 transgenic mice. 
To investigate the developmental impact of Sox3 overexpression, 
we generated transgenic mice using a 37-kb murine Sox3 genomic 
fragment that included an IRES-EGFP reporter cassette. Intrigu-
ingly, 1 of 20 lines that we generated contained an excess of male 
progeny, suggesting XX male sex reversal. Comparison of geno-
type, chromosomal sex, and phenotypic sex of 670 weaned progeny 
revealed that XX male sex reversal had occurred in approximately 
77% of XX hemizygous transgenic (Tg/+) animals. According-
ly, this transgenic line was named Sox3 transgene Sex reversed 
[Tg(Sox3)1Pqt, abbreviated here to Sr]. XX Tg/+ males exhibited 
normal male external genitalia (Figure 1, A–C), with completely 
masculinized reproductive tracts (Figure 1, D–F; n = 4), although 
their testes were significantly smaller than those of XY males and 
lacked sperm (Figure 1, G–I). Transgenic animals exhibited normal 
male mounting behavior.
Sox3 Tg/+ XX gonads express Sox9 and activate the testis differentiation 
pathway. To investigate the mechanism of sex reversal in Sr mice, 
we analyzed gonad morphology and expression of male-specific 
marker genes at 13.5 dpc, when the outcome of sex determination 
is morphologically evident (Figure 2). Most XX Tg/+ gonads had 
a normal male appearance, including the presence of testis cords 
and a coelomic vessel extending across the ventral surface of the 
gonads (Figure 2A). Robust expression of Sox9 and its direct target 
gene Amh (48) was also clearly evident in the testis cords (Figure 
2A). Confocal analysis revealed that EGFP (which completely over-
lapped with Sox3, Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI42580DS1) was 
expressed in Sertoli cells (and some interstitial cells) but not germ 
cells (data not shown), consistent with a direct role for this Sox3 
transgene in Sertoli cell differentiation (Figure 2B). Interestingly, 
some XX Tg/+ gonads exhibited regionally localized/restricted 
expression of the Sox3 transgene (Figure 3, A and B). In these cases, 
the location and intensity of expression from the transgene closely 
correlated with levels of Sox9 expression and the extent of testis 
cord formation. Moreover, this was always seen in the central and 
anterior regions of the gonad, consistent with other cases of ovotes-
tis development and with these regions being the most sensitive to 
male-inducing signals (refs. 49, 50, and Figure 3). A small propor-
tion (5 of 32) of 13.5-dpc XX Tg/+ gonads did not express detect-
able levels of the transgene, and this correlated with the absence of 
both Sox9 expression and testis cord formation (data not shown). 
Taken together, these data demonstrate a strong correlation among 
transgene expression, Sox9 activation, and testicular phenotype.
Sox3 from the Sr transgene mimics Sry in its early expression and function. 
Activation of Sox9 expression in supporting cell precursors by Sry 
is normally required for their differentiation into Sertoli cells and 
subsequent testis development. However, Sox9 itself can induce tes-
tis differentiation when it is ectopically expressed in the early gonad 
or even in cases where the locus has been duplicated (51–53). This 
implies that Sox9 is the only critical target of Sry but also raises the 
question as to whether Sox3, from the Sr transgene, acts like Sry 
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or Sox9. The former would be consistent with the higher degree of 
similarity between the HMG box domains of Sry and Sox3, while the 
latter might reflect the presence of strong transactivation domains 
at the C-termini of both Sox9 and Sox3 (although with little homol-
ogy), whereas no such domain is found in Sry (18, 33).
To address this, it was important to first look at details of expres-
sion from the Sox3 Sr transgene (Sox3-SrTg). Endogenous Sry can 
first be detected at approximately 12 ts, and is shortly followed by 
an upregulation of Sox9 in Sry-positive cells (19). Expression of the 
Sox3 transgene was also first detected at 12 ts (see below), and by 
13 ts, several Sox3-positive cells were clearly present in the XX Tg/+ 
GR (Figure 4A). Some of these were also Sox9-positive (arrows), 
suggesting that Sox3 is directly involved in activating Sox9 expres-
sion in the XX Tg/+ GR. XY GRs had a similar small number of 
Sox9-positive cells, reflecting the initial upregulation of Sox9 by 
Sry (Figure 4A). Consistent with their differentiation along the 
testis pathway, and similar to control XY gonads, XX Tg/+ GRs 
exhibited robust Sox9 expression at 19 ts (approximately 11.5 
dpc), and this regionally coincided with EGFP expression across 
the GR (Figure 4B and data not shown). High-magnification con-
focal analysis revealed coexpression of EGFP and Sox9 consistent 
with cell autonomous induction of Sox9 by Sox3. There was not 
an exact correlation, however, as EGFP-positive, Sox9-negative 
cells were also observed in 11.5-dpc and 12.5-dpc XX Tg/+ gonads 
(Figure 4B and data not shown). These may represent cells fated 
to be Sertoli cells that have yet to upregulate Sox9, or interstitial 
cell precursors. We also found some Sox9-positive, EGFP-negative 
cells in the XX Tg/+ genital ridges (Figure 4B). These probably rep-
resent supporting cell precursors recruited to the Sertoli lineage 
by preexisting Sertoli cells, which occurs in early XY gonads via 
non-cell-autonomous mechanisms (21, 22).
Sox3, like Sry, transactivates the Sox9 testis-specific 
enhancer element TESCO through synergistic interaction 
with Sf1. Sry upregulates Sox9 transcription in the 
testis through binding and activation of a gonad-
specific enhancer, testis-specific enhancer of Sox9 
(TES), synergistically with Sf1 (18, 54). To further 
investigate functional similarity of Sox3 and Sry, we 
performed transactivation assays in vitro using the 
TES core element (TESCO) (18). Consistent with 
previously published data, Sry activated TESCO, but 
only when Sf1 was coexpressed (Figure 4C and ref. 
18). In the absence of Sf1, Sox3 also failed to trans-
activate TESCO. However, cotransfection of Sox3 
and Sf1 resulted in approximately 2-fold activation 
above Sf1 alone, indicating that Sox3, like Sry, syn-
ergistically activates the TESCO enhancer, albeit to a 
slightly lesser degree (ref. 18 and Figure 4C). In con-
trast, greater than 14-fold activation of the TESCO 
reporter was detected when Sox9 and Sf1 were coexpressed com-
pared with Sf1 alone. These results are also consistent with Sox3 
acting like Sry, and not like Sox9, in this context.
Sox3 from the Sr transgene requires endogenous Sox9 to induce testes. 
To further explore whether Sox3 is acting exclusively like Sry, 
or whether it also mimics Sox9 function, we designed a genetic 
experiment to test if the Sox3-SrTg was able to induce sex reversal 
in the absence of Sox9. If Sox3 is functionally equivalent to Sry, 
the Sox3-SrTg should be unable to rescue or induce testis devel-
opment in either XY or XX embryos also null mutant for Sox9. 
Conversely, if Sox3 acts like Sox9, the Sox3-SrTg should be able to 
substitute for both Sry and Sox9 to promote testis cord forma-
tion. Sox3-SrTg;Sox9fl/fl;R26-CreERT2 stud males were bred to Sox9fl/fl 
females. Pregnant females were given tamoxifen at 9.5 and 10.5 
dpc, a protocol found to give efficient Cre-mediated deletion of 
Sox9 and XY female sex reversal (data not shown), or ethanol as a 
vehicle control, and embryos harvested at 12.5 dpc to determine 
genotype and gonadal phenotype. In some experiments, a Tesco-cfp 
transgene was included, to allow a simple assay of Sertoli cell dif-
ferentiation (18). When tamoxifen was omitted, the Sr transgene 
was able to give XX male development, despite the altered genetic 
background (see below). However, after tamoxifen administration, 
we obtained 2 XY Sox3-SrTg;Sox9fl/fl;R26-CreERT2 embryos, one with 
ovotestes and the other with morphologically normal ovaries, and 
a total of 6 XX Sox3-SrTg;Sox9fl/fl;R26-CreERT2 embryos (4 with Tesco-
cfp, 2 without), all of which had gonads with the morphological 
appearance of ovaries (Figure 5). Marker analysis revealed robust 
expression of Foxl2, which is specific to ovarian cell types (Figure 
5). A number of Sox9-positive cells were still present due to inef-
ficient action of tamoxifen in the embryos (data not shown), and 
these are likely to be the same cells that show relatively high levels 
Figure 1
XX Tg/+ adults develop as males. (A–C) External geni-
talia of XX, XY, and XX Tg/+ individuals. Note the male 
phenotype of the XX Tg/+ animal. (D–F) XX, XY and 
XX Tg/+ internal reproductive tracts. Scale bars: 2 mm. 
(G) XY and XX Tg/+ testes. (H and I) Histological sec-
tions of XY and XX Tg/+ testes, respectively, showing 
the absence of sperm in the latter. Scale bars: 100 μm. 
All animals used for this analysis were between 20 and 
24 weeks of age.
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of EGFP expression from the Sox3-SrTg. However, these were not 
present in sufficient numbers to have organized into testis cords or 
to have induced the testis-specific vasculature (Figure 5 and data 
not shown). Collectively, these results provide strong evidence that 
Sox3 from the transgene is not able to compensate for the loss of 
Sox9, and therefore that it behaves like Sry and not like Sox9.
Integration of Sr transgene upstream of the embryonic testis gene 
Aldh1a1. Sex ratios are unaffected in Sox3-null mice, indicating that 
Sox3 is not required for sex determination (40, 45). Furthermore, 
although very low levels of Sox3 transcripts in 11.5-dpc gonads 
have been reported (33), we were unable to detect Sox3 protein 
in wild-type GRs during sex determination (data not shown). We 
therefore postulated that Sox3 was ectopically upregulated in the 
gonads of Sr Tg/+ embryos due to a position 
effect. This was supported by analysis of a sec-
ond independent Sox3 transgenic line in which 
transgene expression was not detected in the 
gonads by immunohistochemistry (11.5 dpc and 
13.5 dpc) or quantitative RT-PCR (qRT-PCR) 
(11.5 dpc) despite comparable CNS expression 
(data not shown). Furthermore, none of 8 XX 
Sox3 transgenic founders that were generated 
exhibited XX male sex reversal (data not shown). 
We initially characterized the Sr integration site 
using FISH analysis of metaphase chromosomes, 
which revealed a single transgene insertion site 
on chromosome 19 in the B/C1 region (Figure 
6B). GenomeWalker, PCR, and Southern blot 
analyses confirmed these data and revealed that 2 
copies of the transgene construct had integrated 
upstream of the retinaldehyde dehydrogenase A1 
(Aldh1a1, also known as Raldh1) gene (Figure 6, 
A, C, and D, and data not shown). The Aldh1a1 
gene product Aldh1a1 catalyzes the conversion 
of retinaldehyde into all-trans-retinoic acid, albe-
it with less efficiency than the related enzymes 
Aldh1a2 and Aldh1a3 (55, 56). Although not 
required for sex determination (57, 58), Aldh1a1 
was previously identified as a testis-enriched 
gene in a subtractive hybridization screen (59) 
and is strongly expressed in Sertoli cells and a 
subset of interstitial cells from 11.5 dpc onward 
(60). To assess whether Aldh1a1 is upregulated 
during differentiation of XX Tg/+ gonads into 
testes, we compared Aldh1a1 and Sox9 expression 
during gonad differentiation by qRT-PCR (Fig-
ure 7A). At 13.5 dpc, Aldh1a1 and Sox9 expres-
sion was considerably higher in XX Tg/+ gonads 
compared with XX controls. However, expression 
of both genes was even higher in XY controls, at 
13.5 dpc and 12.5 dpc, which suggests that acti-
vation of the male pathway is less efficient in the 
XX Tg/+ gonads, consistent with occasional ovo-
testis or ovary development (Figures 2 and 3). In 
situ hybridization and immunohistochemistry 
on 13.5-dpc gonads confirmed that Aldh1a1 was 
strongly expressed in XX Tg/+ gonads, where it 
was localized to Sertoli and some interstitial cells 
in an identical pattern to XY controls (Figure 7, 
B–D, and data not shown).
Coexpression of Sox3 transgene and Aldh1a1 in Sertoli cells in XX Tg/+ 
gonads. To investigate whether proximity of the transgene to Aldh1a1 
could influence its expression, we compared the distribution of 
their gene products in XX Tg/+ gonads. At 13.5 dpc, we observed 
extensive overlap of Sox3 and Aldh1a1 throughout the gonad (Fig-
ure 7, C and D), including the Sertoli cells lining the testis cords, 
suggesting that regulatory elements from Aldh1a1 may be impor-
tant for ectopic transgene expression in the testis (arrows, Figure 
7D). To further investigate the relationship between Aldh1a1 and 
transgene expression during sex determination in XX Tg/+ gonads, 
we compared the distribution of Aldh1a1 and EGFP from 6 to 17 ts 
(Figure 8). Initially, Aldh1a1 was detected in the GR at very low 
levels, and no EGFP was present. By 12 ts, Aldh1a1-positive cells, 
Figure 2
XX Tg/+ gonads have a normal male appearance and express the Sox3 transgene at 
13.5 dpc. (A) XX, XY, and XX Tg/+ 13.5-dpc gonads shown in lateral and medial views 
and analyzed for Sox9 and Amh expression and EGFP fluorescence in unfixed tissue. 
Scale bar: 250 μm. (B) XX Tg/+ 13.5-dpc gonad section stained with EGFP and Sox9 
antibodies. Lower panel shows higher-magnification view of the boxed region. Arrows 
indicate EGFP-positive, Sox9-negative cells in the interstitium. Scale bars: 50 μm.
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detectable by in situ hybridization and immunohistochemistry, 
contained the initial population of EGFP-positive cells (Figure 8, 
box 1). By 17 ts, the number of EGFP-positive cells increased mark-
edly, and most, if not all, of these cells also expressed Aldh1a1, 
albeit at low levels in some cases (Figure 8, box 2). The lack of clear 
singly positive EGFP cells suggests that Aldh1a1 expression may 
provide a permissive regulatory environment for transgene activa-
tion. Once Sox3 transgene expression is initiated in uncommitted 
XX gonads and Sox9 expression is upregulated, a positive feedback 
loop may arise, resulting in robust coexpression of the transgene 
and Aldh1a1 in Sertoli cells (60).
Rearrangements of the SOX3 regulatory region are associated with XX male 
sex reversal in humans. Given that SOX3 function in the CNS is broadly 
conserved in mice and humans and that Sox3 is able to induce sex 
reversal when ectopically expressed in the developing murine GR, it 
is possible that rearrangements at the SOX3 locus are associated with 
human XX male sex reversal. We therefore screened a cohort of 16 
SRY-negative 46, XX male patients for copy number variation using 
Affymetrix 6.0 whole genome SNP (7 patients) and Illumina 1M 
(9 patients) microarrays. Rearrangements covering or in close proxim-
ity to SOX3 were identified in 3 patients (Figure 9, Supplemental Fig-
ures 2 and 3, and Table 1). Patient A contained two microduplications 
of approximately 123 kb and 85 kb, the former of which spanned the 
entire SOX3 gene. Previously published examples of SOX3 duplications 
in 46, XY males have been associated with pituitary hormone deficien-
cies and cognitive defects, whereas 46, XX female carriers have been 
unaffected (38, 47). Consistent with these data, there was no evidence 
of hypopituitarism or intellectual disability in this patient. X-inacti-
vation studies showed no evidence for skewed inactivation in DNA 
derived from lymphocytes (data not shown). FISH analysis using a 
BAC clone covering the SOX3 gene consistently gave a stronger signal 
on one of the X chromosomes, indicative of tandem duplication (Sup-
plemental Figure 3). The centromeric duplication is approximately 
70 kb downstream from the SOX3 gene, very close to a previously 
described deletion-insertion breakpoint in individuals with X-linked 
hypoparathyroidism (61), which was postulated to have a positional 
effect on SOX3 expression. Patient B contained a single 343-kb 
microdeletion immediately upstream of SOX3. Unlike in patient A, 
the coding sequence of SOX3 is not affected in this patient, suggesting 
that altered regulation (and not increased dosage) of SOX3 is the cause 
of XX male sex reversal. Patient C has a more complex phenotype 
that also includes a scrotal hypoplasia, microcephaly, developmental 
delay, and growth retardation. This patient has a large (approximately 
6-Mb) duplication that encompasses SOX3 and at least 18 additional 
distally located genes, overexpression of which probably contributes 
to the phenotypic complexity. Notably, the proximal breakpoint falls 
within the SOX3 regulatory region (62) and is close to the proximal 
SOX3 duplication breakpoint in patient A (Figure 9).
To investigate the possible mechanism of sex reversal in these 
patients, we performed transactivation assays using a human 
SOX9 testis enhancer sequence (hTES) that is homologous to the 
mouse TESCO element (18, 63). hSOX3 and hSRY activated hTES 
approximately 10- and 5-fold, respectively. Activation levels by 
these proteins were further enhanced in the presence of exogenous 
SF1, suggesting synergistic activation, similar to the murine sys-
tem (Figure 10). Together, these data suggest that SOX3 gain of 
function in humans can cause XX male sex reversal.
Discussion
Through characterization of a unique transgenic mouse line, we 
show that ectopic expression of Sox3 in uncommitted XX gonads 
is sufficient to divert the program of ovarian development toward 
testis formation, leading to XX males. Our data indicate that Sox3 
functions as a molecular switch, activating the testis differentiation 
pathway via a mechanism that is functionally analogous to Sry. Fur-
thermore, we provide the first evidence to our knowledge that SOX3 
gain of function in humans can also lead to complete XX male sex 
reversal. Together, these data provide insight into the genetic mech-
anism of mammalian sex determination, the evolution of Sry, and 
the molecular pathology of disorders of sexual development.
Sox3 can function as an analog of Sry. Molecular genetic studies 
carried out mostly in mice and humans, but supported by work in 
other species, provide strong evidence that mammalian testis dif-
ferentiation is critically dependent on a threshold of SOX9 activ-
ity in supporting cell precursors that, once exceeded, suppresses 
the pro-ovarian differentiation program and promotes and then 
reinforces Sertoli cell and subsequent testis differentiation (24, 
53, 64). As shown in mice, Sry along with its cofactor Sf1 bind 
the TESCO enhancer element upstream of Sox9 to mediate its 
initial upregulation (18). Based on the high sequence similarity 
Figure 3
13.5-dpc XX Tg/+ gonads show variable cord formation and 
Sox9 expression that coincides with the spatial localization of 
transgene (EGFP) expression. (A) Sox9 expression and corre-
sponding EGFP expression in representative XX Tg/+ (strong), 
and XX Tg/+ (weak) 13.5-dpc gonads. Scale bar: 250 μm. 
(B) Optical slices of whole mount 12.5-dpc XX Tg/+ and XY 
gonads stained with EGFP (green), Sox9 (red), and Pecam1 
(blue). The dotted lines indicate the outline of the gonads. 
Scale bar: 150 μm.
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of Sox3 and Sry across the HMG domain and the proposed com-
mon evolutionary ancestry of their cognate genes (32), we hypoth-
esized that Sox3 causes XX male sex reversal in Sox3-SrTg mice 
by functioning as a surrogate for Sry. Our data provide several 
lines of evidence to support this view. First, adult Sr XX males 
exhibit complete sex reversal and in this respect are phenotypi-
cally identical to XX Sry transgenic adult males (7). Second, both 
mouse and human SOX3 exhibit in vitro transactivation proper-
ties very similar to those of Sry on TESCO and its human equiva-
lent, including a requirement for Sf1. These are rather weak in 
contrast to the strong activation shown by Sox9. While a strong 
transactivation domain at the C-terminus of Sox3 can be demon-
strated in other contexts (38), this appears not to operate in the 
cotransfection assays reported here. Presumably this is because 
any interaction with Sf1, which could be via the HMG box of Sox3 
(and Sry), is not sufficient to elicit further recruitment of tran-
scriptional coactivators to the complex bound to TESCO. If there 
are no specific requirements for features other than the HMG box, 
then this would provide an explanation for the rapid drift in the 
non-box sequences of SRY during evolution (see below and ref. 
64). Third, there is a close correlation between expression of the 
Sox3 transgene and endogenous Sox9 in the developing XX Sox3-
SrTg/+ gonad, suggesting that Sox3 may activate Sox9 expression 
in vivo. Although a small proportion of Sox9-positive cells do not 
Figure 4
Mechanism of transgene-induced sex reversal and its activation in the gonads. (A) 13 ts XX Tg/+ and XY transverse sections presented as a 
6-μm stack stained with Sox3 and Sox9. Enlargements corresponding to the boxed region are shown on the right. Arrows indicate Sox3/Sox9-
positive cells. Scale bars: 50 μm. (B) Single optical slices of whole mount 11.5-dpc XX, XY, and XX Tg/+ genital ridges stained with Sox9 and 
presented as an overlay with corresponding differential interference contrast (DIC) image. Higher-magnification view of the boxed region in the 
XX Tg/+ genital ridge is shown in the right panel, presented as a 60-μm stack of optical sections and highlighting the extent of colocalization 
between Sox3 and Sox9. Scale bars: 50 μm. In B, genital ridges are oriented so that anterior is to the left and the coelomic epithelium at the top. 
(C) Transactivation experiment using the mouse Sox9 TESCO enhancer reporter. Note that Sox3 and Sry exhibit similar synergistic activation 
of the reporter with SF1, but fail to activate in the absence of SF1. Negative control transfections using a reporter lacking the enhancer are also 
shown (–TESCO). Western blot analysis indicated that comparable levels of Sox3, Sry, and Sox9 protein were expressed (data not shown). Data 
are mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05.
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express the transgene during early XX Tg/+ gonadogenesis, this 
is reminiscent of Sox9-positive/Sry-negative cells that have been 
identified in XY gonads at the same stage, which arise through 
prostaglandin D2 and Fgf signaling (21, 22), suggesting that non-
cell-autonomous recruitment of cells to the Sertoli lineage also 
occurs in XX Tg/+ gonads. Indeed, this might be expected if the 
Sr transgene corresponds to a slightly weak allele of Sry. Fourth, 
the Sox3 transgene is expressed in the central gonad from 12 ts 
(Figures 4 and 8) and is therefore in the correct spatiotemporal 
location to influence the decision of the supporting cell precur-
sors to adopt a male fate (16, 19, 65). Finally, we find that the Sr 
transgene also mimics Sry in vivo, because it depends on the pres-
ence of Sox9 to trigger testis devel-
opment. This again supports the 
notion that Sox3 from the trans-
gene acts like Sry and not Sox9.
In contrast to Sry, transgene 
expression in the gonads of the Sr 
line is maintained in Sertoli cells 
beyond the critical window of sex 
determination. This is not sur-
prising given that Sry is switched 
off once Sox9 reaches the critical 
threshold to trigger Sertoli cell dif-
ferentiation, and it is unlikely that 
Sox3 would respond in the same 
way (66, 67). Instead, Sox3 expres-
sion may be maintained by virtue 
of its integration next to Aldh1a1, 
which itself is activated directly 
or indirectly by Sox9 (see below). 
The functional consequence of 
persistent transgene expression is 
not clear. Sox3 could activate mul-
tiple male-specific target genes, in 
a manner that is analogous to the 
promotion of male development 
by Sox9, although this possibility 
is not supported by the failure of 
the Sr transgene to elicit testis development in the absence of Sox9. 
Alternatively, by virtue of its relatively poor transactivation activity 
in this context (compared with Sox9), Sox3 could interfere with Sox9 
action through competitive binding to its target sites, including to 
the TESCO enhancer. However, although Sry expression is normally 
turned off, this is not essential, as shown with a constitutively active 
Sry transgene, and it naturally stays on for an extended period in 
some species (65, 68). The continuous expression of Sox3 may there-
fore have little or no impact on subsequent testis development.
Delayed testis development and incompletely penetrant sex reversal in Sr 
transgenic XX gonads. While most Sr XX transgenic adults showed com-
plete female-to-male sex reversal (77%), the gonadal development 
Figure 5
The Sox3 transgene is not able to mimic Sox9 in the gonad at 12.5 dpc. (A–F) XY Sox3-SrTg;Sox9fl/fl; 
R26CreERT2 mice were either treated or not treated with tamoxifen (TM). In the absence of TM, the gonad 
developed into a normal testis containing testis cords (A–C). When Sox9 was ablated after TM treatment, 
testis cords were not formed (D and E), and Foxl2-positive cells were detected in the gonad (F). (G–L) 
Similar experiments were performed for XX Sox3-SrTg;Sox9fl/fl;R26CreERT2 mice. The mice developed XX 
sex-reversed testis without TM (G–I). In contrast, TM treatment resulted in ovarian morphology and the 
expression of Foxl2 (J–L). Scale bars: 0.5 mm (A, D, G, and J) and 50 μm (B, C, E, F, H, I, K, and L).
Figure 6
The Sr transgene has integrated upstream of Aldh1a1 on chromosome 
19. (A) Schematic representation of transgene insertion site on chro-
mosome 19 illustrating PCR primer position (black arrows), Southern 
probe (red), and relevant restriction sites. (B) FISH analysis of Tg/+ XY 
metaphase chromosomes. Sox3 transgene (modified RP23-174O19 
BAC) and chromosome 19 (RP23-142D22 BAC) signals are shown 
in red and green, respectively. The inset shows a magnified view of 
chromosome 19 into which the transgene has integrated (19*). Scale 
bars: 2.5 μm; 0.5 μm in inset. (C) PCR assay of genomic DNA using 
primers that flank the transgene integration site. Product is amplified 
from Tg/+ DNA and not from +/+ DNA. All genomic DNA samples were 
shown to be amplifiable using Gapdh primers (data not shown). H2O 
indicates negative control reaction. (D) Southern blot analysis compar-
ing +/+ and Tg/+ DNA digested with KpnI, PstI, and SpeI. Marker sizes 
(kb) are shown on the right. Note the additional bands of expected size 
in each of the Tg/+ tracts. K, KpnI; P, PstI; S, SpeI.
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of XX Tg/+ embryos was often delayed compared with XY controls, 
as evidenced by lower Sox9 and Aldh1a1 expression, fewer Sox9-posi-
tive cells, and incomplete testis cord formation especially at the pos-
terior poles (Figure 3). This phenomenon has also been observed 
with weak Sry alleles such as Y-POS, in which normal onset but 
lower levels of Sry expression and, in some cases, reduced efficacy of 
Sry isoforms leads to reduced Sox9 expression, a delay in testis cord 
development, and XY sex reversal on a C57BL/6 (B6) background 
(17, 69–72). qRT-PCR analysis of Sry and Sox3 transcript levels in 
11.5-dpc XY and XX Tg/+ gonads, respectively, indicated that these 
genes are expressed at similar levels (data not shown), suggesting 
that expression level per se is not the primary cause of the develop-
mental delay. A more likely explanation is that Sox3 is a less efficient 
activator of Sox9, given its weaker transactivation activity on the Sox9 
enhancer element TESCO in the presence of Sf1 (Figure 4). We also 
noticed that increased contribution 
of the pro-ovarian B6 genetic back-
ground (73) reduced the penetrance 
of sex reversal in the Sr line, resulting 
in XX Tg/+ gonads that lacked trans-
gene expression completely (Supple-
mental Figure 4). One explanation 
for this might be the earlier and 
more robust pro-ovarian program 
in B6 gonads preventing the rein-
forcement of transgene expression 
and the male pathway (30, 70, 73). 
Thus, Sox3, like Sry, may function 
in a narrow window of competence 
so that any genetic or environmental 
conditions that reduce its capacity to 
reach the critical threshold required 
for Sertoli cell differentiation lead 
to delayed development of testes, to 
ovotestis, or even to ovaries.
Aldh1a1 and transgene regulation in the gonads. We were unable 
to detect Sox3 protein in the GR of wild-type XY or XX embry-
os, indicating that Sox3 is ectopically expressed in Sr gonads. 
Furthermore, EGFP was not expressed in the GRs of an inde-
pendent Sox3 transgenic line (which does not exhibit XX male 
sex reversal), suggesting that regulatory elements flanking the 
Sr integration site control transgene expression in the gonad. 
Mapping studies indicated that the Sr transgene had inserted 
upstream of Aldh1a1, a gene with sexually dimorphic expression. 
Aldh1a1 is expressed at much higher levels in embryonic testis 
in comparison with ovaries at 12.5 dpc and 13.5 dpc (ref. 60  
and Figure 7), and in the former is restricted to Sertoli cells 
and an undefined population of interstitial cells. The overlap 
of Sox3 and Aldh1a1 expression in XX transgenic gonads at 
these time points suggests that regulatory elements associated 
Figure 7
Expression profile of Aldh1a1/Aldh1a1 
and Sox3 in XY and XX Tg/+ gonads 
from 11.5 to 13.5 dpc. (A) qRT-PCR 
analysis of 11.5- to 13.5-dpc gonads. 
Normalized expression levels of each 
gene are shown relative to β-actin. 
Two cDNA series were analyzed twice 
each, and error bars represent SD of 
the mean of the two series. (B) In situ 
hybridization showing Aldh1a1 expres-
sion in transverse sections of 13.5-dpc 
XY, XX Tg/+, and XX gonads. No sig-
nal was detected using an Aldh1a1 
sense probe. (C) Transverse sections 
of XY, XX Tg/+, and XX 13.5-dpc 
gonads stained with Aldh1a1, Sox3, 
and DAPI. Protein expression lev-
els are consistent with the transcript 
expression analysis shown in B. (D) 
Confocal micrograph of 13.5-dpc XX 
Tg/+ gonad showing the extensive 
overlap in Sox3 and Aldh1a1 expres-
sion. Arrows indicate Sox3/Aldh1a1-
positive cells lining the testis cords. 
Scale bars: 100 μm.
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with testis-specific expression of Aldh1a1 may also control the 
Sr transgene. However, as discussed above, irreversible commit-
ment to a male fate would almost certainly require transgene 
expression in the GR between 12 and 15 ts, prior to Aldh1a1 
expression becoming sexually dimorphic. Intriguingly, Aldh1a1 
and transgene expression overlap in XX Tg/+ gonads at 12–18 ts, 
although coexpression appears to be restricted to a subpopu-
lation of Aldh1a1-expressing cells. These data suggest that 
transcriptional activity from Aldh1a1 in the context of the 
bipotential XX Tg/+ gonad may create a permissive chromatin 
environment that is necessary but not sufficient for transgene 
activation. Perhaps the latter occurs only in cells expressing Sf1 
or another factor restricted to supporting cell precursors. How-
ever, after transgenic XX gonads switch to a testis differentia-
tion program, transgene expression (unlike Sry) is upregulated 
in Sertoli cells. While the regulatory element(s) that direct 
Aldh1a1 expression are not known, a recent study indicates that 
Aldh1a1 is genetically downstream of Sox9 (60). This may have 
implications for the amplification and/or maintenance of Sox3 
expression in Sr gonads and provides a direct link to Sox9, not 
only in establishing the male pathway but also in regulating 
transgene expression. Identification of Aldh1a1 gonadal enhanc-
ers may provide useful tools for transgenic analysis of gonad 
development and would likely lead to a better understanding 
of transgene regulation in Sr transgenic embryos.
Sox3, Sry, and the evolution of the mammalian sex determination switch. 
Comparative cytogenetic and sequence analyses indicate that the 
mammalian sex chromosomes evolved from a pair of autosomes, 
termed the proto-X/Y (36). It has been proposed that Sry was 
generated by a dominant mutation of the proto-Y Sox3 allele in a 
mammalian ancestor approximately 200 million years ago, prior 
to divergence of the therian lineage (32, 36). The functional inter-
changeability of Sox3 and Sry demonstrated here indicates that 
their sole conserved domain, the HMG box, may be all that is criti-
cal for sex determination. This is in agreement with the (exclusive) 
conservation of the HMG domain in SRY genes, transgenic domain 
swap experiments in mice, and the predominance of SRY HMG 
mutations in XY females (35, 74, 75). The finding that Sox3 can 
promote male development when expressed in the genital ridge, in 
a manner that is comparable to Sry, adds further evidence against 
the hypothesis that Sox3 is required for ovary development or that 
Sry is a dominant negative version of Sox3, repressing the latter’s 
activity (or expression) (76). Instead it implies that the evolution of 
Sry involved a mutation event that led to expression of one allele of 
Sox3 (the proto-Sry) within the supporting cell lineage of the geni-
tal ridge. This mutation may have been subtle, with the proto-Sry 
retaining the conserved pattern of Sox3 expression within the CNS 
and elsewhere, or it could have involved a deletion or transloca-
tion, where most of the latter was lost. In several species examined, 
including mouse, rat, and human, Sry is expressed in parts of the 
developing and adult CNS (77–79), although given the rapid evolu-
tion of Sry flanking sequences, it will be a challenge to prove wheth-
er this reflects conservation of specific regulatory elements or the 
acquisition of new ones. Concomitant with the change in proto-Sry 
expression, Sox9 must have acquired the ability to respond to it. 
If, however, Sox9 was already involved in regulating its own expres-
sion within the Sertoli cell lineage of the therian ancestor, as shown 
in the mouse (18), then this capacity to respond to the proto-Sry 
may have already existed. To this end, recent evolutionary analy-
ses have demonstrated that conserved elements within TESCO are 
present in all tetrapods, suggesting that mechanisms of Sox9 regu-
lation are conserved and precede the evolution of Sry (63).
Figure 8
Expression of Aldh1a1 and EGFP in the gonadal ridge of XX Tg/+ gonads at 6–17 ts. Immunohistochemistry and in situ hybridization of serial 
transverse sections showing EGFP and Aldh1a1 distribution in 6–17 ts embryos. Given the low level of Aldh1a1 protein in the XX Tg/+ GR 
during these early stages of sex determination, the expression of Aldh1a1 in adjacent sections is included at each stage for comparison. 
Aldh1a1/Aldh1a1 is first observed at 6 ts (magnified in box inset). Aldh1a1/Aldh1a1 is detected in a diffuse pattern at 12 ts. A rare EGFP-positive 
cell is found within a population of Aldh1a1-positive cells in the GR at this stage (magnified in box 1). At 17 ts, Aldh1a1/Aldh1a1 becomes more 
restricted, while the abundance of EGFP within the GR increases (magnified in box 2). Scale bars: 100 μm.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 1   January 2011 337
SOX3 rearrangement is associated with XX male sex reversal in humans. 
Cases of SRY-negative XX male sex reversal are particularly intrigu-
ing, and their genetic basis has been debated extensively in the lit-
erature since SRY was identified almost 20 years ago. To date, loss 
of only one gene, RSPO1, has been shown to be associated with 
a clear XX male sex reversal condition, albeit in an unusual syn-
dromic form of this disorder involving skin abnormalities (palmo-
plantar hyperkeratosis and predisposition to squamous cell carci-
noma; ref. 26). Genomic rearrangements and mutations of SOX9, 
SOX10, and SF1 have also been detected in rare cases of XX male 
and XY female sex reversal (80–82), although the molecular etiol-
ogy of most cases is unknown. In this study, we have identified 
SOX3 rearrangements in 3 patients with XX male sex reversal. 
Furthermore, we show that hSOX3 transactivates a human TES-
like enhancer sequence, suggesting that human SOX3, like its 
murine counterpart, can functionally compensate for SRY. In con-
trast to the murine TESCO analysis, transactivation experiments 
using hTES were performed in CHO cells in which endogenous 
SF1 is already present. This is likely to function in synergy with 
hSOX3 and hSRY to give the observed limited transactivation in 
the absence of exogenous SF1 (82). Taken together, these data 
raise two possible mechanisms by which SOX3 could activate the 
male differentiation pathway in these patients: increased dosage 
or ectopic expression. Based on previous reports of SOX3 duplica-
tion in humans (which is associated with hypopituitarism and 
variable mild intellectual disability; refs. 38, 47) and the absence 
Table 1
Clinical summary of 46, XX male patients with SOX3 rearrangements
	 Patient	A	 Patient	B	 Patient	C
Age at evaluation 30 yr Endocrine: 19 yr; histology: 26 yr 19 mo
Height 165 cm 167.5 cm 75.2 cm
FSHA 22.0 mIU/ml 69.0 mIU/ml 
LHB 11.1 IU/L 35.0 IU/l 
ProlactinC 17.9 μg/l 3.0 μg/l 
Free testosteroneD 1.92 ng/dl (early morning) 0.86 ng/dl (afternoon measurement)
Testicular volume ~5 ml ~6 ml and soft Right testicle appears smaller
   than left testicle
Penis size  Shaft length, 10.2 cm; shaft diameter, 2.6 cm Shaft length, 3.4 cm
Genitals and testis  Histology: Atrophic changes with loss of normal Hypoplastic scrotum; 
  spermatogenesis; thickening and hyalinization of testes are retractile and
  the tubular basal lamina and diminished number can be brought down
  of interstitial cells; normal spermatic cords
Secondary sexual Normal Tanner stage 5 pubic hair and penile development N/A
 characteristics  with small testis; onset age, 13 yr
Developmental issues  Gender dysphoria from 6 years;  Developmental delay; microcephaly; 
  referred to behavior therapist growth retardation
All units given in conventional units (defined in ref. 95). AFSH: male reference range 5–20 mIU/ml. BLH: male reference range, 5–20 IU/l. CProlactin refer-
ence: 5–20 μg/l. DNormal male free testosterone, >6.5 ng/dl (96).
Figure 9
SOX3 rearrangements in 46, XX males. An image derived from the UCSC genome browser (http://genome.ucsc.edu) showing the location of the 
rearrangements identified in patients A–C in relation to the SOX3 gene. Also shown are rearrangements previously identified in healthy individu-
als (as recorded in the Database of Genomic Variants; http://projects.tcag.ca/variation), including CNVs and an inversion. It is noteworthy that 
duplication breakpoints in patients A and C are in close proximity to other known CNV/inversion breakpoints, suggesting structural or sequence 
motifs that may be responsible for recurrent rearrangements. Numbering corresponds to nucleotide position on the X chromosome (chrX), based 
on reference sequence hg18.
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of Sox3 protein in murine bipotential gonads, it is unlikely that 
increased dosage of SOX3 in these 3 patients is the mechanism 
responsible for the sex reversal. It is more probable that rearrange-
ment of the SOX3 locus, through duplication or deletion, leads to 
ectopic gonadal expression and subsequent activation of the male 
pathway at a critical stage of sex determination. As conserved ele-
ments that direct regional SOX3 expression are located across at 
least a 500-kb interval flanking the gene, it is plausible that these 
rearrangements activate SOX3 expression in the gonad, perhaps 
by generating a gonadal enhancer or ablation of a repression ele-
ment (62). Indeed, the centromeric duplication breakpoint in 
patients A and C is in close proximity to a previously described 
deletion-insertion breakpoint in individuals with X-linked hypo-
parathyroidism, which was proposed to induce ectopic SOX3 
expression (61). While it would be very interesting to assess the 
impact of SOX3 rearrangements on embryonic gonadal expres-
sion in humans, this is obviously not possible. However, based 
on our analysis of the Sr transgenic mice, these are exactly the 
kind of mutations that could reasonably be expected to occur in 
patients with XX male sex reversal. Notably, SOX3 expression was 
not detected in a lymphoblast cell line from patient B (the only 
patient from whom a cell line was available; data not shown), sug-
gesting that the rearrangement has not caused widespread ectopic 
SOX3 expression, which instead may be relatively restricted and 
include the developing gonad.
Taken together, these data provide a molecular entry point into 
the etiology of XX male sex reversal in humans. It is worth not-
ing the high frequency of SOX3 rearrangements in 46, XX male 
patients (19%), suggesting that this may be a significant cause of 
this disorder. Indeed, this may be an underestimate given that bal-
anced rearrangements/translocations would not have been detect-
ed by our analysis. Further chromosomal and molecular analysis of 
DSD patient cohorts is therefore required to determine the relative 
contribution of SOX3 rearrangements to the underlying pathology 
of this poorly understood group of conditions.
Methods
Generation of Sr transgenic mice. The transgene construct was derived from 
a modified BAC clone (RP23-174O19) containing an internal ribosome 
entry site–EGFP (IRES-EGFP) reporter cassette inserted into the 3′UTR of 
Sox3 using homologous recombination (83). The PCR product for recom-
bineering contained a 5′ Sox3 homology arm, IRES-EGFP reporter, FRT site, 
kanamycin resistance cassette, FRT site, and 3′ Sox3 homology arm and was 
generated using Expand High Fidelity PCR System (Roche) amplification 
of a modified pIRES2-EGFP plasmid (BD Biosciences — Clontech; forward 
primer: CAGCTCTTCGCCCCCACCCCGCCCCACACCCCCCAC-
GTTGGGACGCCTTGGCCCCTCTCCCTCCCCCCCCCCTAA; Reverse 
primer: CGCACTTCAAATTTCGGACCCGCAAAATTATCAGGACTC-
CAGCATATTGGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCATT-
TATTCTGTCTTTTTATTGCCGTC (Sox3 homology sequence is in bold and 
FRT site in italics). The kanamycin resistance cassette was removed in bacte-
ria prior to transgene preparation using an FLP recombinase expression vec-
tor. The 37-kb transgene spanned positions 58,136,727–58,172,890 of the X 
chromosome (July 2007 [NCBI 39/mm9] assembly) and contained approxi-
mately 26 kb and 8 kb of 5′ and 3′ Sox3 genomic sequence, respectively. It was 
generated by PmeI/AhdI digestion, purified by agarose gel electrophoresis and 
microdialysis, and injected into the pronucleus of C57BL/6 × CBA F1 zygotes. 
The Sr line was established from an XY founder animal and was maintained 
on a C57BL/6 × CBA mixed genetic background. Routine genotyping was 
performed by PCR amplification of genomic DNA derived from tail biopsies 
(weanlings) or embryonic/yolk sac tissue (embryos) using PCR (Sry prim-
ers: CACTGGCCTTTTCTCCTACC and CATGGCATGCTGTATTGACC; 
Gapdh primers: CTTGCTCAGTGTCCTTGCTG and ACCCAGAAGACTGT-
GGATGG; Egfp: ATGGTGAGCAAGGGCGAGGAGCTGTT and CTGGGT-
GCTCAGGTAGTGGTTGTC; cycle conditions: denaturation 95°C 2 min-
utes; amplification 95°C 30 seconds, 60°C 30 seconds, 72°C 3 minutes 
30 seconds (35 cycles); final extension 72°C 7 minutes, 25°C 5 minutes). 
For the Sox9 rescue experiment, previously published lines that contain a 
homozygous floxed allele of Sox9 (Sox9fl/fl) (84) and a tamoxifen-inducible 
CreERT2 knocked into the Rosa26 locus (R26-CreERT2) (85) maintained on 
a F1 (C57BL/10 × CBA) genetic background were used. Tamoxifen (Sigma-
Aldrich) was dissolved in ethanol at 100 mg/ml. To activate Cre-ERT2, the 
tamoxifen solution was diluted with sunflower oil to the final concentration 
of 10 mg/ml, and 0.3 ml of the diluted solution was administered by gavage 
to pregnant mice at 9.5 and 10.5 dpc. All animal experimentation was per-
formed in accordance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes and was approved by the University of Adelaide 
Animal Ethics Committee or by the UK Home Office.
FISH of chromosomes. For mouse studies, FISH probes were directly 
labeled with spectrum orange/spectrum green using commercial kits 
(Vysis). Hybridization to metaphase spreads and fluorescence detec-
tion were performed on metaphase preparations as previously described 
(86). For human studies, FISH using BAC RP11-51C14 was carried out 
on metaphase spreads obtained from the 46, XX male patient according 
to previously described methods (87).
Cloning the Sr integration site. The 5′ integration site was identified by 
GenomeWalker (BD Biosciences — Clontech) amplification of Tg/+ genom-
ic DNA using nested Sox3 transgene primers (Sox3GSP1: ACAGCCTT-
GTGAGTAGGTATGCTCTTG; Sox3GSP2: CTTCTTTGTGCGGACCCT-
TATTCCAAG). The sequence immediately 5′ to the transgene integration 
site was identified as a long interspersed nuclear element (LINE) repeat 
using RepeatMasker (http://www.repeatmasker.org/) and could not be 
unequivocally assigned to a genomic location using BLAST (http://www.
ncbi.nlm.nih.gov/) or BLAT (http://genome.ucsc.edu/) analysis. However, 
a LINE repeat that perfectly matched this transgene-flanking sequence was 
identified by megaBLAST analysis of the mouse genome sequence trace 
Figure 10
SOX3 activates the hTES. Human SOX3 (100 ng) activates hTES-luc 
(1.6 μg) (10–fold) compared with human SRY (100 ng) (5-fold) in CHO 
cells. In the presence of added SF1 (20 ng), further transactivation 
occurs with both SOX3 (25-fold) and SRY (20-fold) (n = 2–3). Error 
bars represent SD. Unless otherwise indicated, statistical comparisons 
were made between fold activations of expression vector and control 
empty vector. ***P < 0.001, **P < 0.01.
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archive (http://www.ncbi.nlm.nih.gov/blast/mmtrace.shtml), and a contig 
was assembled through reiterative interrogation. PCR amplification using 
unique flanking sequence and transgene primers generated a product from 
Tg/+ genomic DNA and not +/+ genomic DNA (primers: ACAGCCTTGT-
GAGTAGGTATGCTCTTG and TGGCTGTGGTAACCATTCATAAGG-
TAG; cycle conditions: denaturation 95°C 2 minutes; amplification 95°C 
30 seconds, 60°C 30 seconds, 72°C 3 minutes [35 cycles]; final extension 
72°C 7 minutes, 25°C 5 minutes). Sequencing confirmed the authentic-
ity of this PCR product. To further confirm the integration site of the 
Sr transgene, standard Southern blot analysis was performed using a 
32P-labeled chromosome 19–specific probe that spanned positions 
20547495–20548089 (July 2007 assembly).
Immunohistochemistry, histology, and imaging. Mouse embryos were dissected 
in PBS, fixed in 4% PFA/PBS, cryoprotected in 30% sucrose, and embedded 
in OCT medium. Sections (10 μm) were prepared using a Leica CM1900 
cryostat. Blocking in PBS/0.1% Triton X-100/1% BSA/10% heat-inactivated 
horse serum was performed for 30 minutes, followed by overnight incuba-
tion at 4°C in the same solution containing diluted primary antibody. Sec-
tions were washed 3 times for 10 minutes in PBS and incubated in diluted 
secondary antibody at 4°C for 6 hours. After washing 3 times for 10 min-
utes each in PBS, slides were mounted in Prolong Gold Antifade (Molecu-
lar Probes, Invitrogen) and imaged using a Zeiss Axioplan 2 microscope 
and AxioCam MRm with Axiovision software. Antibodies and their corre-
sponding dilutions were: rabbit anti-ALDH1A1 (Abcam Ab24343; 1:200), 
goat anti-SOX3 (R&D Systems; 1:100), rabbit anti-EGFP (Abcam; 1:2,000), 
goat anti-EGFP (Rockland; 1:400), rabbit anti-SOX9 (19) (1:1,000), goat 
anti-SOX9 (R&D Systems; 1:300), rabbit anti-FOXL2 (gift from Dagmar 
Wilhelm, Institute for Molecular Bioscience, The University of Queensland, 
Brisbane, Queensland, Australia; 1:1,000), Cy3–donkey anti-rabbit (Jackson 
ImmunoResearch Laboratories Inc.; 1:400), Cy5–donkey anti-goat (Jackson 
ImmunoResearch Laboratories Inc.; 1:400), Cy3–donkey anti-rabbit (Rock-
land; 1:1,000), Cy3–donkey anti-goat (Jackson ImmunoResearch Labora-
tories Inc.; 1:400) and Cy5–donkey anti-rabbit (Jackson ImmunoResearch 
Laboratories Inc.; 1:400) and Alexa Fluor 488–donkey anti-goat (Molecular 
Probes, Invitrogen; 1:400). Adult testis were fixed in Bouin’s fixative and 
stained using hematoxylin and eosin. Whole mount images were captured 
using a Nikon SMZ1000 GFP dissecting microscope with AnalySIS soft-
ware and processed using Adobe Photoshop CS. Confocal images were cap-
tured on a Leica Sp5 Spectral scanning confocal microscope and processed 
using Leica Application Suite — Advanced Fluorescence 1.8.0 build 1346. 
Select images were subject to median measurements using a radius of 3 
with 4 iterations to decrease graininess from the Cy5 fluorophore.
Whole mount and section in situ hybridization. Whole mount in situ hybridization 
and in situ hybridization of 10-μm cryosections were performed as described 
previously (88, 89). The Aldh1a1 plasmid was a gift from Peter Koopman (Insti-
tute for Molecular Bioscience, The University of Queensland). The Sox9 and 
Amh plasmids were published previously (19, 90).
RNA extraction and qRT-PCR analysis. RNA extractions were performed on GR 
explants and contained mesonephros unless stated otherwise. For 10.5- and 
11.5-dpc embryos, the two genital ridges were pooled from each embryo, while 
individual gonads and associated mesonephros were isolated from 12.5-dpc 
and 13.5-dpc embryos. Samples were homogenized by brief sonication prior 
to being passed over QIAshredder columns (QIAGEN). RNA was isolated 
using the RNeasy Plus kit (QIAGEN) and analyzed for RNA integrity and 
concentration on a Bioanalyzer (Agilent). Fifty nanograms of each sample 
was reverse transcribed using the High Capacity RNA-to-cDNA kit (Applied 
Biosystems). qRT-PCR was performed using Fast SYBR Green Master Mix 
(Applied Biosystems) and run on an ABI 7500 StepOnePlus system. Gene-
specific primer pairs were designed to cross intron-exon boundaries. The 
sequences and lengths of amplified products were: Aldh1a1 (158 bp) 5′-CCTT-
GCATTGTGTTTGCAGATG-3′ and 5′-GCTCGCTCAACACTCCTTTTC-3′; 
Sox9 (106 bp) 5′-GCAAGCTGGCAAAGTTGATCT-3′ and 5′-GCTGCT-
CAGTTCACCGATG-3′; EGFP (95 bp) 5′-ACGACGGCAACTACAAGACC-3′ 
and 5′-GTCCTCCTTGAAGTCGATGC-3′; and β-actin (89 bp) 5′-CTGCCT-
GACGGCCAGG-3′ and 5′-GATTCCATACCCAAGAAGGAAGG-3′. Efficiency 
of the amplification was verified by analysis of standard curves. No template 
and minus-RT controls were performed to ensure signal was cDNA-specific.
Cotransfection assays. Transactivation assays using the mouse TESCO 
reporter were performed in COS7 cells as described previously (18). DNA 
encoding human SRY, SF1, and mouse and human SOX3 were contained 
within the pcDNA3 mammalian expression plasmid (Clontech). The hTES 
sequence was amplified from the BAC contig clone RP11-84E24 (Gen-
Bank AC007461), located on chromosome 17, by PCR using a forward 
oligonucleotide containing an XhoI restriction site (GATCATCCGCTC-
GAGCGGTGTTGAGAAGTGAACTGT) and a reverse oligonucleotide 
containing an AccI restriction site (GATGGCCGGTCGACCGGCCACTT-
GGCTCAAATCTCAC). The resultant PCR product was cloned into the 
multiple cloning site of the E1b-luc reporter construct (91). hTES cotrans-
fection assays were conducted in the CHO cell line cultured in Dulbecco’s 
medium supplemented with 10% fetal bovine serum and l-glutamine in an 
atmosphere of 5% CO2. Briefly, cells were seeded at a density of 2.3 × 105 cells 
per well in a 6-well plate 24 hours prior to transfection. Forty-eight hours 
after transfection, the culture media was removed, cell lysate collected, 
and luciferase reporter activity measured according to the manufacturer’s 
instructions (Promega). Reporter activity was normalized to β-galactosidase 
as an internal control (Promega). Empty reporter, E1b-luc, transfection data 
were subtracted from each transfection condition to standardize data. Fold 
activations were determined by dividing by vector-alone transfection data.
Microarray analysis. Genomic DNA from patients A and B was hybridized to 
an Affymetrix Genome-Wide Human SNP 6.0 array at the Australian Genome 
Research Facility according to the manufacturer’s instructions. Data analysis 
was performed with An R Object-oriented Microarray Analysis (AROMA) algo-
rithm (92). Multiplex ligation–dependent probe amplification (MLPA) analy-
sis to confirm the duplication was performed as previously described (93). 
Genomic DNA from patient C was hybridized to an Illumina Human1M-Duo 
DNA Analysis BeadChip at the Southern California Genotyping Consortium 
according to the manufacturer’s instructions. Data analysis was performed 
using CNV partition v2.3.4 on Illumina Genome Studio (94).
Clinical data. Clinical data for patients A, B, and C are summarized in 
Table 1. These studies were approved by the Human Research Ethics Com-
mittee of the Royal Children’s Hospital, Melbourne, and the UCLA Insti-
tutional Review Board. Written informed consent was obtained from par-
ticipants or their parents/guardians.
Patient A is a male of European descent who presented at 30 years of 
age for infertility. He had no significant past medical history and was 
healthy at time of presentation. His height was 165 cm, and he weighed 
64 kg, with no abnormal symptoms. He underwent puberty between 14 
and 15 years of age. Family history was not significant, and there was no 
consanguinity. Infertility was indicated by two spermograms, which con-
firmed azoospermia. Testicular biopsy was not performed. The patient 
was SRY-negative (data not shown). Parental DNA was not available.
Patient B is a 35-year-old of European descent. Gender dysphoria was 
reported from around 6 years, leading ultimately to gender reassignment 
surgery at age 26 years. Puberty commenced around age 14. At age 19, 
height was 167.5 cm, weight 73.5 kg, with no medical problems apart from 
ongoing gender identity issues. The external genitalia were normal male, 
apart from small, soft 6-ml testes (by orchidometer), subsequently mea-
sured at less than 4 ml (by orchidometer) at age 25 years. Shaving was infre-
quent, and there was little body hair, but axillary and pubic hair was nor-
mal (minimal abdominal extension). Primary hypogonadism was evident 
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at age 19 years, with follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) both elevated, at 69 mIU/ml and 35 mIU/ml, respectively, 
and random free testosterone level being low, at 8.7 pg/ml. Serum prolac-
tin was normal. Histological examination following gender reassignment 
surgery showed atrophic changes in the testes, with loss of normal sper-
matogenesis, thickening and hyalinization of the tubular basal lamina, and 
diminished number of interstitial cells. Spermatic cords were histologically 
normal, as was the penis. The patient was SRY-negative in both peripheral 
blood and testicular tissue. The SOX3 rearrangement was not present in his 
mother. DNA was not available for the father.
Patient C is a boy of Mexican origin who presented at 19 months with 
failure to thrive and developmental delay (height 75.2 cm [<5th percentile]). 
There were no significant problems during pregnancy or the newborn peri-
od, and cytogenetic analysis showed that this child was 46, XX, SRY-negative. 
Family history was significant only for learning disabilities. There was no 
consanguinity. No endocrine evaluation or parental DNA was available.
Statistics. Statistical analysis for transactivation assays was conducted 
using a 2-tailed, paired Student’s t test, and P < 0.05 was considered signifi-
cant. Error bars indicate the mean ± SEM in Figure 4 and SD in Figure 10.
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